Donald P Tashkin1. 1. David Geffen School of Medicine at UCLA, Los Angeles, California, USA. dtashkin@mednet.ucla.edu
Abstract
PURPOSE OF REVIEW: This article reviews findings from longitudinal observational studies in both general and chronic obstructive pulmonary disease (COPD) populations, as well as from intervention trials in COPD, in which the annual rate of decline in forced expired volume in 1 s (FEV₁) has been measured. The purpose of the review is to describe the individual variability in rates of decline in FEV₁ within these populations, explore the factors contributing to this variability and discuss its implications. RECENT FINDINGS: Individual rates of decline in FEV₁ have been found to vary considerably across participants with COPD in both observational cohorts and intervention trials from decreases as rapid as 150-200 ml per year to increases of up to approximately 150 ml per year, with mean rates of decline ranging from 33 to 69 ml per year. Aside from technical and biologic (e.g., time of day, season, weather, fatigue) sources of variation, other influential factors have included smoking status (most notably current versus former smoking), baseline smoking intensity, baseline lung function, airway hyperresponsiveness, exacerbation frequency, and, variably, age and sex. The presence of emphysema may also be a determinant, as well as certain biomarkers and gene variants. SUMMARY: The wide distribution of individual rates of decline in FEV₁ includes especially rapid and slow declines. Future research is needed to identify biomarkers that both are predictive of a rapid decline within individuals who might then be targeted for special intervention and might also serve as surrogate endpoints in interventional trials.
PURPOSE OF REVIEW: This article reviews findings from longitudinal observational studies in both general and chronic obstructive pulmonary disease (COPD) populations, as well as from intervention trials in COPD, in which the annual rate of decline in forced expired volume in 1 s (FEV₁) has been measured. The purpose of the review is to describe the individual variability in rates of decline in FEV₁ within these populations, explore the factors contributing to this variability and discuss its implications. RECENT FINDINGS: Individual rates of decline in FEV₁ have been found to vary considerably across participants with COPD in both observational cohorts and intervention trials from decreases as rapid as 150-200 ml per year to increases of up to approximately 150 ml per year, with mean rates of decline ranging from 33 to 69 ml per year. Aside from technical and biologic (e.g., time of day, season, weather, fatigue) sources of variation, other influential factors have included smoking status (most notably current versus former smoking), baseline smoking intensity, baseline lung function, airway hyperresponsiveness, exacerbation frequency, and, variably, age and sex. The presence of emphysema may also be a determinant, as well as certain biomarkers and gene variants. SUMMARY: The wide distribution of individual rates of decline in FEV₁ includes especially rapid and slow declines. Future research is needed to identify biomarkers that both are predictive of a rapid decline within individuals who might then be targeted for special intervention and might also serve as surrogate endpoints in interventional trials.
Authors: Catherine H Miele; Matthew R Grigsby; Trishul Siddharthan; Robert H Gilman; J Jaime Miranda; Antonio Bernabe-Ortiz; Robert A Wise; William Checkley Journal: Thorax Date: 2018-07-30 Impact factor: 9.139
Authors: Sara Ongay; Marijke Sikma; Peter Horvatovich; Jos Hermans; Bruce E Miller; Nick H T Ten Hacken; Rainer Bischoff Journal: Chronic Obstr Pulm Dis Date: 2016-03-01
Authors: Donald P Tashkin; Ning Li; David Halpin; Eric Kleerup; Marc Decramer; Bartolome Celli; Robert Elashoff Journal: Respir Med Date: 2013-08-22 Impact factor: 3.415
Authors: José Leiva-Fernández; Francisca Leiva-Fernández; Antonio García-Ruiz; Daniel Prados-Torres; Pilar Barnestein-Fonseca Journal: BMC Pulm Med Date: 2014-04-25 Impact factor: 3.317
Authors: Hannah R Whittaker; Hana Müllerova; Deborah Jarvis; Neil C Barnes; Paul W Jones; Chris H Compton; Steven J Kiddle; Jennifer K Quint Journal: Int J Chron Obstruct Pulmon Dis Date: 2019-05-23
Authors: Jiska B Snoeck-Stroband; Therese S Lapperre; Peter J Sterk; Pieter S Hiemstra; Henk A Thiadens; H Marike Boezen; Nick H T Ten Hacken; Huib A M Kerstjens; Dirkje S Postma; Wim Timens; Jacob K Sont Journal: PLoS One Date: 2015-12-10 Impact factor: 3.240